Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & Therapeutics

SANTA MONICA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today...
October 21, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021

SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
August 25, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Participate in September Investor Conferences

SANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company’s senior management team will participate...
August 05, 2021 16:01 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
July 22, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
July 20, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
July 12, 2021 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer

Mr. Ruth led the highly successful launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdoseHe joins Opiant at a time when the Company is developing and...
July 06, 2021 16:01 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose

Data demonstrate rapid absorption and higher plasma concentrations versus an intramuscular injection (p<0.0001) Results confirm findings of initial pilot PK studySANTA MONICA, Calif., July 06, 2021...
May 24, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
May 18, 2021 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT

SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...